Furthermore, genetic and molecular features of multiple myeloma, including high-risk cytogenetics (e.g., del(17p), t(4;14)) or TP53 mutations, may influence both ferritin levels and clinical outcomes [41]. This evidence concerns the gene TP53 and AL amyloidosis.